Uncategorised

Parallel trade in the life sciences sector – recent developments

Tine Carmeliet

Please join us on Tuesday, 26 January 2021 for a webinar on the key developments in the parallel trade of pharmaceuticals in 2020.  Tine Carmeliet, Nele De Backer, Francesca Miotto, Geert Glas and Nieke Vanavermaete will talk you through recent decisions and developments in the field of parallel trade, review the impact of both Brexit Read More

European Commission completes current cycle of pay-for-delay probes with fines imposed on Teva and Cephalon

Thomas Masterman

On 26 November 2020, the European Commission (Commission) issued a decision fining pharmaceutical companies Teva and Cephalon EUR60.5 million for infringing Article 101 TFEU by agreeing to delay the entry of a cheaper generic version of Cephalon’s sleep disorder drug modafinil (the Decision). While the Decision completes the current cycle of the Commission’s “pay-for-delay” investigations, Read More

China: Patent Law Amendment brings sea change to pharmaceutical patent regime

Jill Ge

On 17 October 2020, the top legislature in China passed the Fourth Amendment to the PRC Patent Law (“Amendment”) which will take effect on 1 June 2021. The Amendment is significant as it introduces patent linkage and patent term extensions for pharmaceutical patents. The Amendment reflects the commitments China made in the U.S.-China Phase 1 Read More

Covid-19 coronavirus – the UK’s preparation for a vaccine

Megan McMellon

The UK’s vaccine portfolio The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses: AstraZeneca and the University of Oxford (adenoviral vector vaccine, 100m doses); Johnson & Johnson (adenoviral vector vaccine, 30m doses, with an option to acquire an addition 22m Read More

France – Update of national early meetings guide for medicines evaluation

Jeanne Fabre

On 29 April 2020, the French High Health Authority (HAS) updated its guide on national early meetings for medicines evaluation. As part of its action plan for innovative medicines and its work programme presented at the beginning of 2020, the HAS has revised its guide to early meetings which aims to support businesses in the Read More